Emerging and re-emerging viral infections have become a major concern in global public health systems. Increased international travel, environmental changes, and rapid population movement allow infectious diseases to spread quickly across countries and continents. As a result, accurate laboratory diagnostics are essential for early pathogen detection, outbreak monitoring, and effective clinical management. Improving diagnostic reliability is therefore a critical step in controlling viral diseases and reducing transmission risks.
Over the past decades, several external quality assurance (EQA) programs have been developed for important viral pathogens such as Human Immunodeficiency Virus (HIV), herpes simplex virus, cytomegalovirus, and enteroviruses. These quality assessment programs are widely implemented across Europe through commercial organizations and scientific collaborations. Their primary objective is to improve the accuracy, reproducibility, and reliability of virological diagnostic testing performed in clinical laboratories.
Despite these advances, many rare but clinically significant viral pathogens remain insufficiently covered by standardized quality control systems. Hantaviruses represent one of these neglected diagnostic challenges. Although hantavirus infections are relatively uncommon in many regions, they can cause severe and potentially life-threatening disease, making reliable laboratory diagnosis extremely important.
Hantaviruses and Human Infection
Hantaviruses belong to the Bunyaviridae family and are naturally maintained in rodent reservoirs worldwide. Human infection usually occurs through inhalation of aerosolized particles contaminated with rodent urine, saliva, or feces. While many infections remain asymptomatic, symptomatic cases in Europe are commonly classified as Hemorrhagic Fever with Renal Syndrome (HFRS).
Clinical manifestations of HFRS typically include:
- High fever lasting several days
- Severe headache
- Abdominal and flank pain
- Renal dysfunction
- Acute kidney injury in severe cases
The incidence of hantavirus infection varies considerably across Europe. Some countries report only a limited number of cases annually, while regions such as Finland may experience hundreds or even thousands of infections per year. Because symptoms may overlap with other febrile illnesses, laboratory confirmation through serological testing is essential for accurate diagnosis.
Importance of External Quality Assessment in Hantavirus Diagnostics
Most hantavirus diagnostic assays used in clinical laboratories are either commercial serological kits or internally developed in-house methods. Although these tests often undergo internal validation, many have historically lacked participation in external quality control programs. Without standardized inter-laboratory evaluation, diagnostic sensitivity and specificity may vary significantly between laboratories.
To address this issue, the European Network for the Diagnostics of Imported Viral Diseases established a hantavirus diagnostic quality assessment initiative across Europe. The objective was to evaluate the performance of participating laboratories in detecting hantavirus-specific antibodies and to identify limitations in current diagnostic systems.
Two separate evaluation phases were conducted:
- A preliminary pre-evaluation panel (PEP) in 1999
- A larger external quality assurance (EQA) serum panel involving 20 samples
These studies aimed to assess the reliability of serological testing for hantavirus IgG and IgM antibodies under real laboratory conditions.
Hantavirus Pre-Evaluation Panel (PEP)
Serum Sample Preparation
The pre-evaluation panel consisted of four serum samples prepared using:
- One hantavirus-positive serum containing IgG antibodies against Puumala hantavirus
- One hantavirus-negative serum
The positive serum was serially diluted at different concentrations to evaluate diagnostic sensitivity. Participating laboratories were asked to analyze the samples for both IgG and IgM antibodies using their routine diagnostic methods.
Participating European Laboratories
Thirteen laboratories from several European countries participated in the study, including institutions from:
- Finland
- Germany
- Greece
- Belgium
- Austria
- Portugal
- Spain
- Slovenia
- France
- Netherlands
This multinational participation provided an important overview of hantavirus diagnostic practices across Europe.
Pre-Evaluation Results
The initial PEP results revealed important differences in diagnostic sensitivity:
- Approximately 64% of IgG-positive samples were correctly identified
- Around 92% of IgG-negative samples were correctly reported
- IgM-negative samples were correctly classified by all laboratories
These findings demonstrated that test specificity was generally acceptable, but sensitivity remained insufficient, particularly for low-titer antibody samples.
External Quality Assurance (EQA) Program
Expanded Serum Panel Design
The first full EQA panel included 20 human serum samples obtained from multiple ENIVD collaborators. The sample panel contained:
- Strong IgG and IgM positive sera
- IgG-positive / IgM-negative samples
- Borderline-positive samples
- Completely negative sera
- Multireactive sera with nonspecific antibody reactions
To evaluate assay sensitivity, highly positive samples were distributed at multiple dilution levels.
Sample Processing and Distribution
Serum samples were:
- Aliquoted into standardized tubes
- Freeze-dried for transport stability
- Evaluated by immunoblotting before shipment
- Distributed to laboratories by regular mail
Participants were instructed to rehydrate the samples before testing. No restrictions were imposed regarding the diagnostic method used, allowing laboratories to apply their standard in-house or commercial assays.
Participating Laboratories
Eighteen laboratories from Europe, Canada, and South Africa participated in the EQA program. This broader participation improved the overall assessment of international hantavirus diagnostic capability.
Performance of Serological Diagnostic Methods
IgG Detection Results
The EQA study demonstrated that:
- Approximately 76% of IgG-positive samples were correctly identified
- Nearly 97% of IgG-negative samples were correctly classified
These results confirmed that diagnostic specificity was generally high, but sensitivity still required improvement.
IgM Detection Results
The detection of acute hantavirus infection through IgM testing showed lower performance:
- Only 53% of IgM-positive samples were correctly detected
- About 98% of IgM-negative samples were correctly reported
This reduced sensitivity is clinically important because failure to detect IgM antibodies may lead to missed diagnoses during early infection stages.
Comparison of Diagnostic Technologies
Several serological methods were used during the EQA program, including:
- Immunoblotting (IB)
- Enzyme Immunoassays (EIA)
- Immunofluorescence Assays (IFA)
Performance Comparison
The study found relatively similar overall performance among these technologies:
IgM Detection
- Immunoblot: ~87%
- EIA: ~87%
- IFA: ~80%
IgG Detection
- Immunoblot: ~90%
- EIA: ~77%
- IFA: ~85%
Immunoblot assays appeared slightly more sensitive than EIA or IFA systems, especially for low-titer samples.
Commercial vs In-House Assays
An important finding was that in-house assays performed similarly to commercial diagnostic kits:
IgM Testing
- In-house assays: ~83%
- Commercial assays: ~87%
IgG Testing
- In-house assays: ~80%
- Commercial assays: ~81%
This suggests that assay quality depends more on optimization and validation than on whether the system is commercial or laboratory-developed.
Challenges in Hantavirus Serological Diagnosis
Low Antibody Titers
Many distributed serum samples were intentionally diluted to assess diagnostic sensitivity. This resulted in low antibody concentrations that were difficult for some assays to detect accurately.
Low-titer samples are particularly important because patients in early-stage infection may also present weak antibody responses.
Sensitivity Limitations
The major limitation identified in the study was insufficient sensitivity for detecting acute infections. Missing IgM-positive cases could delay diagnosis and clinical management, especially in severe HFRS cases.
Strain Identification Complexity
Some laboratories attempted to identify specific hantavirus strains. However, experts noted that accurate strain differentiation generally requires neutralization testing, which was not included in the study protocol. Consequently, strain-level interpretation should be approached carefully in routine diagnostics.
Importance of Continuous External Quality Assurance
The study clearly demonstrated the importance of regular external quality control programs for rare viral pathogens such as hantaviruses. Although these infections are less common than viruses like HIV, reliable diagnostics remain essential because of their severe clinical consequences.
Regular EQA programs provide several benefits:
- Improvement of diagnostic sensitivity
- Standardization between laboratories
- Identification of assay weaknesses
- Validation of new diagnostic technologies
- Increased reliability of patient results
Continuous monitoring and optimization of serological assays are necessary to ensure accurate hantavirus detection across clinical laboratories worldwide.
Conclusion
Quality control measures are essential for improving the serological diagnosis of hantavirus infections. The European hantavirus EQA studies demonstrated that although specificity of current diagnostic systems is generally high, sensitivity—particularly for IgM detection—still requires significant improvement.
Both commercial and in-house assays showed comparable performance, while immunoblot methods demonstrated slightly higher sensitivity than EIA and IFA systems. The findings also highlighted the importance of standardized external quality assurance programs in maintaining reliable laboratory diagnostics for emerging viral diseases.
As emerging infectious diseases continue to pose global health risks, strengthening diagnostic quality assurance systems for rare pathogens like hantaviruses remains a critical component of public health preparedness and outbreak response.